EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Serum Lipidomics Profiling Identify Novel Biomarkers of Distal Symmetrical Polyneuropathy in Type 1 Diabetes

Tik Muk iD, Tina Okdahl, Marietta Kokla iD, Tommi Suvitaival iD, Gurjeet Kaur iD, Ismo M Mattila iD, Simon M Kienle iD, Christian Buhl, Knud Yderstræde, Troels S Jensen iD, Peter Rossing iD, Flemming Pociot iD und 7 weitere

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Tik Muk und 18 weiteren Autor:innen. Beteiligte Einrichtung: Steno Diabetes Center Copenhagen, Herlev, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Lipidomics, Diabetic Neuropathies, Lipids. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Distal symmetrical polyneuropathy (DSPN) is a common complication of type 1 diabetes (T1D), yet validated biomarkers for early detection or prognosis are lacking. Metabolic disturbances driven by chronic hyperglycemia and dyslipidemia contribute to DSPN development and progression.

Methods

We used untargeted serum liquid chromatography‐mass spectrometry lipidomics to identify DSPN biomarkers. The discovery cohort included 153 individuals with T1D (109 with and 44 without DSPN) and 50 non‐diabetic controls. The independent validation cohort included 99 individuals with T1D with established DSPN status. Key lipids were identified using multivariate modelling, followed by ANCOVA and adjusted post hoc tests.

Results

A total of 543 lipid species were identified in the discovery cohort. Among these, 14 lipids were associated with DSPN. Of which, 6 lipids, namely Cer(d42:1), PC(36:4), LPC(16:0), LPE(18:1), PE(36:2), and PE(O‐40:5) or PE(P‐40:4), showed a clear pattern among non‐diabetic individuals, people affected by T1D with and without DSPN. In the validation cohort, 3 of the 6 initially identified lipids showed the same directional changes as in the discovery cohort. A logistic regression model combining the six lipid biomarkers with HbA1c, diastolic blood pressure, and age achieved AUCs of 0.83 (95% CI, 0.76–0.91) in the discovery cohort and 0.81 (95% CI, 0.73–0.90) in the validation cohort for detecting DSPN in T1D. AUC improvement was not significant by DeLong's test in either cohort ( p = 0.086 and 0.089) but was significant when combined using Fisher's method (χ 2 = 9.7, p = 0.045). Additionally, 22 lipid species differed significantly between painful and painless DSPN.

Conclusions

We identified a reproducible lipidomic signature discriminating DSPN in type 1 diabetes. Painful DSPN was characterized by reduced unsaturated PC/PE and increased sphingolipids, offering new insight into disease pathophysiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1LipidomicsDiabetic NeuropathiesLipidsPolyneuropathiesHumansBiomarkersFemaleMaleAdultCase-Control StudiesLiquid Chromatography-Mass SpectrometryMiddle AgedCohort Studies

Stichwörter der Autor:innen

distal symmetrical polyneuropathydyslipidemialipid biomarkerslipidomicspainful neuropathyserum lipid profilingtype 1 diabetesuntargeted liquid chromatography‐mass spectrometry lipidomics

Substanzen

BiomarkersLipids

Autor:innen und Institutionen

  • Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital and Clinical Institute, Aalborg University, Aalborg, Denmark.
  • Steno Diabetes Center Aarhus, Aarhus, Denmark.
  • Steno Diabetes Center Odense, Odense, Denmark.
  • Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Tik Muk, Marietta Kokla, Tommi Suvitaival, Gurjeet Kaur, Ismo M Mattila, Simon M Kienle, Troels S Jensen, Peter Rossing, Flemming Pociot, Birgitte Brock, Cristina Legido-Quigley, Páll Karlsson, Christian S Hansen, Christina Brock, Joachim Størling, Karolina Sulek

Förderung

  • Novo Nordisk Fonden

Zitieren

APA

Muk, T., Okdahl, T., Kokla, M., Suvitaival, T., Kaur, G., Mattila, I. M., Kienle, S. M., Buhl, C., Yderstræde, K., Jensen, T. S., Rossing, P., Pociot, F., Brock, B., Legido-Quigley, C., Karlsson, P., Hansen, C. S., Brock, C., Størling, J., & Sulek, K. (2026). Serum Lipidomics Profiling Identify Novel Biomarkers of Distal Symmetrical Polyneuropathy in Type 1 Diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71257

Vancouver

Muk T, Okdahl T, Kokla M, Suvitaival T, Kaur G, Mattila IM, et al. Serum Lipidomics Profiling Identify Novel Biomarkers of Distal Symmetrical Polyneuropathy in Type 1 Diabetes. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71257

BibTeX
@article{Muk2026,
  author = {Muk, Tik and Okdahl, Tina and Kokla, Marietta and Suvitaival, Tommi and Kaur, Gurjeet and Mattila, Ismo M and Kienle, Simon M and Buhl, Christian and Yderstræde, Knud and Jensen, Troels S and Rossing, Peter and Pociot, Flemming and Brock, Birgitte and Legido-Quigley, Cristina and Karlsson, Páll and Hansen, Christian S and Brock, Christina and Størling, Joachim and Sulek, Karolina},
  title = {Serum Lipidomics Profiling Identify Novel Biomarkers of Distal Symmetrical Polyneuropathy in Type 1 Diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71257}
}
Kostenlos starten →